What three mechanisms actually matter
A supplement that doesn't address at least one of the following is not meaningfully relevant to H. pylori:
- Urease inhibition — reducing H. pylori's ability to neutralise stomach acid and survive
- Anti-adhesion activity — reducing H. pylori's ability to anchor to the stomach wall[2]
- Mucosal repair — supporting the stomach lining that H. pylori has damaged
The comparison below is structured around these three criteria — not brand popularity, marketing claims, or general wellness positioning.
The three supplements compared
TumGard is a flavonoid-concentrated supplement formulated specifically for H. pylori-related gut damage. Its active compounds — quercetin, myricetin, catechin, and licorice-derived glabridin — inhibit H. pylori's urease enzyme, reduce bacterial adhesion to the stomach wall, and support mucosal repair through the EGFR/ERK pathway.
iThrive Essentials GutConnect is a probiotic and prebiotic blend formulated for gut microbiome recovery. Its Lactobacillus and Bifidobacterium strains are well-evidenced for restoring gut flora balance after antibiotic courses — clinically relevant post-H. pylori treatment. It does not target H. pylori directly: it does not inhibit urease, block bacterial adhesion, or act on the EGFR/ERK mucosal repair pathway.
Miduty Berberine is a general antimicrobial supplement based on berberine HCl. Berberine has demonstrated some antimicrobial activity against H. pylori in in vitro studies, but evidence for the specific mechanisms that matter most — urease inhibition, anti-adhesion, and mucosal repair — is limited. It has no established action on the EGFR/ERK pathway.
Side-by-side comparison
| Feature | TumGard | iThrive GutConnect | Miduty Berberine |
|---|---|---|---|
| Urease inhibition | ✓ Yes — quercetin, myricetin, catechin | ✗ No | Partial |
| Anti-adhesion activity | ✓ Yes — licorice flavonoids | ✗ No | ✗ No |
| Mucosal repair (EGFR/ERK) | ✓ Yes | ✗ No | ✗ No |
| Microbiome rebuild post-antibiotics | Indirect | ✓ Primary mechanism | Partial |
| Price / 20-day supply | ₹799 | ₹1,299 | ₹600 (30-day) |
| Money-back guarantee | 60 days | 30 days | 30 days |
| PMC-indexed evidence | ✓ Multiple compound studies | ✓ General probiotic evidence | Moderate |
| Format | Jam (after meals) | Powder | Capsules |
Who should use TumGard for H. pylori support
- People who have completed antibiotic treatment and want to support stomach lining recovery
- People with confirmed H. pylori who are waiting for or supplementing medical treatment
- People with recurring acidity, failed antacids, and a high likelihood of H. pylori — given India's 62% endoscopy positivity rate
- People who have tested negative for H. pylori but have chronic gastritis or mucosal inflammation
TumGard is not a replacement for antibiotics in active, symptomatic H. pylori infection. If you have a confirmed H. pylori diagnosis with significant symptoms, signs of a peptic ulcer, or significant unexplained weight loss alongside gut symptoms — see a doctor first.
Use TumGard in addition to, not instead of, appropriate medical treatment.
References
- Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. International Journal of Antimicrobial Agents. 2005;26(5):343–356. PMID 16323269. Establishes flavonoid mechanisms including urease inhibition and membrane disruption against H. pylori — the evidence basis for TumGard's urease-inhibition claim.
- O'Mahony R, Al-Khtheeri H, Weerasekera D, et al. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World Journal of Gastroenterology. 2005;11(47):7499–7507. PMC4250616. Documents anti-adhesion activity of licorice-derived flavonoids against H. pylori gastric epithelial adhesion — the mechanism underpinning TumGard's anti-adhesion claim.
- Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea. JAMA. 2012;307(18):1959–1969. PMID 22570464. Meta-analysis confirming Lactobacillus and Bifidobacterium efficacy for post-antibiotic gut flora restoration — the evidence basis for iThrive GutConnect's primary use case.
The mechanism-based comparison rests on published literature: flavonoid urease inhibition (Cushnie & Lamb, 2005), licorice anti-adhesion activity (O'Mahony et al., 2005), and probiotic efficacy post-antibiotics (Hempel et al., 2012). The clinical context is provided by the TumGard India Gut Health Report 2026: 62% H. pylori positivity in endoscopy patients and 54% of symptomatic individuals already on antacids or PPIs without relief.